Trial
NCT03496298
Effect of Efpeglenatide on Cardiovascular Outcomes
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Hanmi Pharmaceutical Company Limited
Condition
Type 2 Diabetes Mellitus
Intervention
Efpeglenatide (SAR439977)
Why stopped
Sponsor decision to cancel TRIAL, not related to safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15